Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2015 Mar 4;17(2):215–224. doi: 10.1016/j.neo.2014.12.011

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2015 The Authors

This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

PMC Copyright notice

Figure S1 — Tumor growth of NU12. Mean % of growth of NU12 tumors during treatment with sunitinib. Treatment with sunitinib was started when tumors had reached a tumor volume of 100 to 200 mm³ (Day 10) and continued until Day 3. Three days later mice were injected with ¹¹¹In-cG250. Percentage tumor growth was set at 100% at start of treatment with sunitinib. Tumor growth is strongly inhibited by sunitinib treatment (black line) in comparison to control (red line).

Figure S2 Tumor growth of SK-RC-52. Mean % of growth of SK-RC-52 tumors during treatment with sunitinib. Treatment with sunitinib was started when tumors had reached a tumor volume of 100 to 200 mm³ (Day 10) and continued until Day 3. Three days later mice were injected with ¹¹¹In-cG250. Percentage tumor growth was set at 100% at start of treatment with sunitinib. Tumor growth is stabilized by sunitinib treatment (black line) in comparison to control (red line).

Figure S1 — Tumor growth of NU12. Mean % of growth of NU12 tumors during treatment with sunitinib. Treatment with sunitinib was started when tumors had reached a tumor volume of 100 to 200 mm³ (Day 10) and continued until Day 3. Three days later mice were injected with ¹¹¹In-cG250. Percentage tumor growth was set at 100% at start of treatment with sunitinib. Tumor growth is strongly inhibited by sunitinib treatment (black line) in comparison to control (red line).

Figure S2 Tumor growth of SK-RC-52. Mean % of growth of SK-RC-52 tumors during treatment with sunitinib. Treatment with sunitinib was started when tumors had reached a tumor volume of 100 to 200 mm³ (Day 10) and continued until Day 3. Three days later mice were injected with ¹¹¹In-cG250. Percentage tumor growth was set at 100% at start of treatment with sunitinib. Tumor growth is stabilized by sunitinib treatment (black line) in comparison to control (red line).